文献速递分子诊断质量管理与危急值

整合质量指标的FMEA用于HPV基因分型检测全过程风险评估

Failure Mode and Effects Analysis (FMEA) integrating quality indicators for risk assessment of the total testing process in human papillomavirus genotyping testing: a proactive risk analysis model for molecular diagnostics.
PubMed 文献 · Clin Chem Lab Med · 2025-08-29

本研究将失效模式与效应分析(FMEA)与质量指标(QI)整合,构建HPV基因分型检测的全过程前瞻性风险评估模型,以符合ISO 15189:2022并提升诊断准确性。多学科团队在分析前、分析中和分析后阶段实施FMEA,并通过分子诊断专用MQI模型将Sigma度量融入框架。结果识别5个高风险失效模式并成功降至可接受水平(RPN<40),建立包含14项分析前、25项分析中和3项分析后QI的MQI,35项可评估QI中1项高风险和3项中风险均通过纠正措施处理。

要点

  • FMEA整合QI可提高HPV基因分型检测风险评估的客观性。
  • 5个高风险失效模式经优化后RPN降低20-80%。
  • 建立的MQI含14项分析前、25项分析中、3项分析后QI。

核心结论

  • 整合FMEA与QI的模型可用于HPV基因分型检测全过程风险评估,较传统方法提高客观性并支持多维分析。

研究设计与样本

  • 多学科团队设计并实施覆盖分析前、分析中和分析后阶段的详细FMEA。
  • 通过分子诊断专用MQI模型将Sigma度量整合入FMEA框架。
  • 风险量化采用严重度、发生度(来自1年QI数据)和检测度评分(1-5分),计算RPN以排序失效模式。
  • 对高风险项(RPN≥40)实施强制干预。

主要发现

  • 识别5个高风险失效模式(如样本错误识别、数据分析错误),经流程优化和标准化后降至可接受水平(RPN<40),RPN降低20-80%。
  • 建立分子诊断专用MQI,包含14项分析前、25项分析中和3项分析后QI。
  • 对35项可评估QI进行基于QI的风险评估,发现1项高风险QI(信息系统故障导致结果错误)和3项中风险QI,均通过纠正措施处理。

关键数值与推荐

  • 高风险失效模式定义为RPN≥40,需强制干预。
  • 严重度、发生度和检测度均采用1-5分评分。
  • 35项可评估QI中1项高风险、3项中风险。

临床怎么用

  • 可将FMEA与QI整合模型用于HPV基因分型检测的全过程风险识别与优先干预。
  • 利用1年QI数据估算发生度,提高风险评估的客观性。
  • 对RPN≥40的高风险失效模式实施强制干预并验证降至RPN<40。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop a proactive risk assessment model for human papillomavirus (HPV) genotyping testing by integrating Failure Mode and Effects Analysis (FMEA) with quality indicators (QIs), ensuring compliance with ISO 15189:2022 and improving diagnostic accuracy. METHODS: A multidisciplinary team designed and performed detailed FMEA across pre-analytical, analytical, and post-analytical phases of HPV genotyping testing. To improve objectivity, we integrated Sigma metrics into the FMEA framework through a molecular diagnostics-specific model of QIs (MQI). The FMEA model systematically identified testing phases, potential failure modes, their effects, root causes, and existing controls. Risk was quantified using Severity, Occurrence (from 1-year QI data), and Detection scores (1-5 scale). Risk Priority Numbers (RPNs) were calculated (Severity × Occurrence × Detection) to prioritize failure modes, with mandatory interventions implemented for high-risk items (RPN≥40). RESULTS: Five high-risk failure modes (e.g., sample misidentification, data analysis errors) were identified and successfully mitigated to acceptable levels (RPN<40) through process optimization and standardization, achieving RPN reductions of 20-80 %. We established a molecular diagnostics-specific MQI, comprising 14 pre-analytical, 25 analytical, and three post-analytical phase QIs. QI-based risk assessment of 35 evaluable QIs for HPV genotyping testing revealed one high-risk QI ("Incorrect results due to information system failures") and three medium-risk QIs, all of which were addressed through corrective actions. CONCLUSIONS: This study developed an integrated FMEA-QI model for HPV genotyping testing, establishing both a traditional FMEA framework and a molecular diagnostics-specific MQI. The combined approach improves risk assessment objectivity and enables multidimensional analysis compared to conventional methods.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Li T, He Y, Chen Y, et al. Failure Mode and Effects Analysis (FMEA) integrating quality indicators for risk assessment of the total testing process in human papillomavirus genotyping testing: a proactive risk analysis model for molecular diagnostics. Clin Chem Lab Med. 2025. PMID: 40879430. doi:10.1515/cclm-2025-0598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。